Recon: AbbVie’s Parkinson’s drug succeeds in Phase 3 study; Merck’s Keytruda combo misses survival endpoint in late-stage ovarian cancer study
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States